CN111632021A - Probiotics toothpaste for preventing gingival atrophy - Google Patents

Probiotics toothpaste for preventing gingival atrophy Download PDF

Info

Publication number
CN111632021A
CN111632021A CN202010732967.4A CN202010732967A CN111632021A CN 111632021 A CN111632021 A CN 111632021A CN 202010732967 A CN202010732967 A CN 202010732967A CN 111632021 A CN111632021 A CN 111632021A
Authority
CN
China
Prior art keywords
vitamin
probiotics
toothpaste
lactobacillus
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010732967.4A
Other languages
Chinese (zh)
Inventor
赵国盛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Aishan Commodity Co ltd
Original Assignee
Zhejiang Aishan Commodity Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Aishan Commodity Co ltd filed Critical Zhejiang Aishan Commodity Co ltd
Priority to CN202010732967.4A priority Critical patent/CN111632021A/en
Publication of CN111632021A publication Critical patent/CN111632021A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention discloses probiotic -protecting toothpaste for preventing gingival atrophy, which comprises an abrasive, a wetting agent, an adhesive, a foaming agent and auxiliary medicines, wherein the auxiliary medicines comprise 0.8-1.5% of vitamin E, 6-13% of vitamin B2, 1-9% of probiotics, 0.02-0.1% of CPC cetylpyridinium chloride and 1-2% of zinc citrate by weight, and the probiotics comprise 40-60% of Lactobacillus acidophilus LA85, 20-30% of Lactobacillus salivarius LS97 and 15-35% of Lactobacillus paracasei LC 86. The probiotic toothpaste for preventing gingival atrophy has good effects of improving the nutritional status of periodontal tissues, reducing gingival atrophy and preventing and treating dental caries.

Description

Probiotics toothpaste for preventing gingival atrophy
Technical Field
The invention relates to the technical field of toothpaste, in particular to probiotic toothpaste for preventing gingival atrophy.
Background
Gingival atrophy is a common clinically intractable disease, and is a retraction-type lesion of gingival and alveolar bone tissues, which is characterized by gingival retraction and exposure of a tooth neck or a tooth root. The main causes of periodontal atrophy are: compression of the gum by the dental calculus at the neck of the tooth; long-term disuse of the teeth at the site or systemic factors; mechanical irritation from improper brushing methods; the prosthesis compresses the gingiva, etc. To the extent that the gums are receded, tooth root exposure can lead to tooth loosening, which is a significant cause of tooth loss and sensitivity.
Various toothpastes having excellent properties have been developed to keep human teeth in a healthy state, but it is difficult to achieve desired effects after components of the toothpaste are absorbed through oral mucosa in the market. In addition, although vitamin E has good effect, the cost of using natural vitamin E is high, and commercial advantages are lost if effective content price is reached, for example, the effect of using artificially synthesized vitamin E is not ideal.
Disclosure of Invention
The invention aims to provide probiotic -protecting toothpaste for preventing gingival atrophy, which has good effects of improving the nutritional status of periodontal tissues, reducing the gingival atrophy and preventing and treating dental caries.
In order to achieve the purpose, the invention provides probiotic -protecting toothpaste for preventing gingival atrophy, which comprises an abrasive, a wetting agent, an adhesive, a foaming agent and an auxiliary medicament, wherein the auxiliary medicament comprises 0.8-1.5% of vitamin E, 6-13% of vitamin B2, 1-9% of probiotic, 0.02-0.1% of CPC cetylpyridinium chloride and 1-2% of zinc citrate by weight, and the probiotic is prepared by compounding 40-60% of Lactobacillus acidophilus LA85, 20-30% of Lactobacillus salivarius LS97 and 15-35% of Lactobacillus paracasei LC 86.
Preferably, the auxiliary medicine comprises 0.8% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.06% of CPC cetylpyridinium chloride and 1.2% of zinc citrate by weight ratio.
Preferably, the auxiliary medicine comprises 1.5% of vitamin E, 7% of vitamin B2, 1% of probiotics, 0.09% of CPC cetylpyridinium chloride and 1.6% of zinc citrate by weight ratio.
Preferably, the auxiliary medicine comprises 1.1% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.03% of CPC cetylpyridinium chloride and 1.5% of zinc citrate by weight ratio.
Preferably, the probiotics are compounded by 51% of lactobacillus acidophilus LA85, 28% of lactobacillus salivarius LS97 and 21% of lactobacillus paracasei LC 86.
Preferably, the probiotics are compounded by 43% of lactobacillus acidophilus LA85, 25% of lactobacillus salivarius LS97 and 16% of lactobacillus paracasei LC 86.
Preferably, the probiotics are compounded by 58% of lactobacillus acidophilus LA85, 21% of lactobacillus salivarius LS97 and 17% of lactobacillus paracasei LC 86.
Therefore, the probiotic toothpaste for preventing gingival atrophy has good effects of improving the nutritional status of periodontal tissues, reducing gingival atrophy and preventing and treating dental caries.
The invention has the following effects of the components:
vitamin E has effects in scavenging free radicals, resisting aging and promoting health. Vitamin E can reduce lipofuscin content and protect cell membrane fluidity of tissue organ cells. In addition, the oral care liquid can prevent blood fat from rising, reduce the content of cholesterol, improve the function of vascular endothelium and help to carry out good oral care on rich blood vessels in the oral cavity. Secondly, vitamin E can help to repair oral mucosa, promote ulcer healing, prevent peroxidation of unsaturated fatty acid, and stabilize cell membrane. During the healing process, four enzymes such as LDH, MDH, ICDH and G6PDH are promoted, and the wound healing is accelerated.
Vitamin B2 is a component of the prosthetic group of internal enzymes of xanthases, and the xanthases play a hydrogen transfer role in biological oxidation reduction, can promote development and cell regeneration, promote normal growth of skin, nails and hair, help to prevent and eliminate inflammatory reactions in oral cavity, lips, tongue and skin, and are collectively called as the main physiological function of vitamin B2 of oral reproductive syndrome, namely as coenzyme to promote metabolism.
The mutual matching of the vitamin E and the vitamin B2 can effectively relieve the dental ulcer, the vitamin E forms a protective film on the ulcer surface, the local blood circulation is promoted, the pain is relieved, and the healing of the ulcer surface is accelerated.
The probiotics promote the molecule rigidity state, reduce the oxidation-reduction potential, obstruct the external stress, and ensure the tolerance stability and the efficacy of the product. Wherein, the lactobacillus salivarius LS97 has the functions of adhering and colonizing oral mucosa. The thallus contains a large amount of peptidoglycan, lipoteichoic acid and extracellular protein, passes through oral epithelial cells and oral mucosa, and effectively regulates the oral immune system of a host and balances the steady-state environment of the oral cavity through the action of cell permeability and cell receptors.
The lactobacillus paracasei LC86 can produce various bacteriocins to inhibit pathogenic bacteria, has broad-spectrum antibacterial effect, and can be matched with lactobacillus salivarius to help regulate oral flora balance. Lactobacillus acidophilus LA85 has the ability to adhere to and colonize tooth surfaces. The lactobacillus acidophilus LA85 competes with pathogenic bacteria for binding sites on the mucosal surface, reduces colonization of the pathogenic bacteria, changes the micro-ecological environment by adjusting the pH value and the oxidation-reduction reaction potential, and plays a role by stimulating nonspecific immune reaction and regulating humoral immunity and cellular immunity.
CPC cetylpyridinium chloride, pyridinium chloride is a cationic quaternary ammonium compound that reduces or inhibits the formation of dental plaque by inhibiting and killing bacteria primarily through reduction in surface tension.
The zinc citrate has effects of removing halitosis, smoke stain, dental calculus and relieving inflammation. Zinc can inhibit the growth of bacteria, destroy the formation of bacterial plaque, and influence the transport of bacteria to cane sugar, thereby reducing the acid production capacity of bacteria, and the bacteriostatic activity of zinc is related to the form of metal products. The zinc has the other characteristic of being capable of staying in oral mucosa and bacterial plaque for a long time to maintain bacteriostatic concentration. Clinical experiments prove that the antibacterial ability of the zinc is usually stronger than that of the zinc used alone when the zinc is used together with other medicines for inhibiting bacterial plaque or the zinc is added into toothpaste, and meanwhile, the antibacterial intensity of the zinc is not increased along with the increase of the concentration, but the antibacterial duration is influenced by the concentration. In addition, the long-term use of the medicine has no obvious side effect.
The technical solution of the present invention is further described in detail by the following examples.
Detailed Description
The embodiments of the present invention will be further explained below.
A probiotic toothpaste for preventing gingival atrophy comprises an abrasive, a wetting agent, an adhesive, a foaming agent and an auxiliary medicament, wherein the auxiliary medicament comprises 0.8-1.5% of vitamin E, 6-13% of vitamin B2, 1-9% of probiotic, 0.02-0.1% of CPC cetylpyridinium chloride and 1-2% of zinc citrate, and the probiotic is prepared by compounding 40-60% of Lactobacillus acidophilus LA85, 20-30% of Lactobacillus salivarius LS97 and 15-35% of Lactobacillus paracasei LC 86.
Example one
The auxiliary medicine comprises 0.8% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.06% of CPC cetylpyridinium chloride and 1.2% of zinc citrate by weight ratio.
Example two
The auxiliary medicine comprises 1.5% of vitamin E, 7% of vitamin B2, 1% of probiotics, 0.09% of CPC cetylpyridinium chloride and 1.6% of zinc citrate by weight ratio.
EXAMPLE III
The auxiliary medicine comprises 1.1% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.03% of CPC cetylpyridinium chloride and 1.5% of zinc citrate by weight ratio.
Example four
The probiotics is prepared by compounding 51% of lactobacillus acidophilus LA85, 28% of lactobacillus salivarius LS97 and 21% of lactobacillus paracasei LC 86.
EXAMPLE five
The probiotics is prepared by compounding 43% of lactobacillus acidophilus LA85, 25% of lactobacillus salivarius LS97 and 16% of lactobacillus paracasei LC 86.
EXAMPLE six
The probiotics is prepared by compounding 58% of lactobacillus acidophilus LA85, 21% of lactobacillus salivarius LS97 and 17% of lactobacillus paracasei LC 86.
Test of
The test method comprises the following steps: 90 human subjects with swelling and aching of gum, oral ulcer and oral disease of gum atrophy are selected at an outpatient clinic and are randomly divided into three groups, and the auxiliary medicines of the first embodiment, the second embodiment and the third embodiment are respectively used, wherein probiotics are all prepared according to the proportion of the fourth embodiment. Each person brushes teeth with toothpaste once every morning and evening, about 1-3g of the toothpaste is used once, statistics is carried out after 2 weeks continuously, and the results are as follows.
Example one Example two EXAMPLE III
Obvious effect 25 24 26
Takes effect generally 3 3 2
Has no obvious effect 2 3 2
The toothpaste of the invention can obviously improve the gingival atrophy, toughen the atrophic gingiva and even induce the regeneration of the gingiva, thereby being capable of supporting the moving teeth more tenaciously and providing good nutrition for the teeth. Exciting is that some of these subjects with gingival atrophy were found to have smaller and better coverage of the previously exposed root area two months after using the toothpaste of example one, and a thin layer of pale pink neogingival tissue was observed at the interface between the teeth and gums in some subjects.
Therefore, the probiotic toothpaste for preventing gingival atrophy has good effects of improving the nutritional status of periodontal tissues, reducing gingival atrophy and preventing and treating dental caries.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that modifications can be made by those skilled in the art without departing from the principle of the present invention, and these modifications should also be construed as the protection scope of the present invention.

Claims (7)

1. A probiotic toothpaste for preventing gingival atrophy comprises an abrasive, a wetting agent, a binding agent and a foaming agent, and is characterized in that: the compound feed also comprises an auxiliary drug, wherein the auxiliary drug comprises 0.8-1.5% of vitamin E, 6-13% of vitamin B2, 1-9% of probiotics, 0.02-0.1% of CPC cetylpyridinium chloride and 1-2% of zinc citrate by weight, and the probiotics comprise 40-60% of Lactobacillus acidophilus LA85, 20-30% of Lactobacillus salivarius LS97 and 15-35% of Lactobacillus paracasei LC 86.
2. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the auxiliary medicine comprises 0.8% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.06% of CPC cetylpyridinium chloride and 1.2% of zinc citrate by weight ratio.
3. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the auxiliary medicine comprises 1.5% of vitamin E, 7% of vitamin B2, 1% of probiotics, 0.09% of CPC cetylpyridinium chloride and 1.6% of zinc citrate by weight ratio.
4. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the auxiliary medicine comprises 1.1% of vitamin E, 15% of vitamin B2, 3% of probiotics, 0.03% of CPC cetylpyridinium chloride and 1.5% of zinc citrate by weight ratio.
5. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the probiotics is prepared by compounding 51% of lactobacillus acidophilus LA85, 28% of lactobacillus salivarius LS97 and 21% of lactobacillus paracasei LC 86.
6. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the probiotics is prepared by compounding 43% of lactobacillus acidophilus LA85, 25% of lactobacillus salivarius LS97 and 16% of lactobacillus paracasei LC 86.
7. The probiotic toothpaste for preventing gingival atrophy according to claim 1, wherein: the probiotics is prepared by compounding 58% of lactobacillus acidophilus LA85, 21% of lactobacillus salivarius LS97 and 17% of lactobacillus paracasei LC 86.
CN202010732967.4A 2020-07-27 2020-07-27 Probiotics toothpaste for preventing gingival atrophy Pending CN111632021A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010732967.4A CN111632021A (en) 2020-07-27 2020-07-27 Probiotics toothpaste for preventing gingival atrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010732967.4A CN111632021A (en) 2020-07-27 2020-07-27 Probiotics toothpaste for preventing gingival atrophy

Publications (1)

Publication Number Publication Date
CN111632021A true CN111632021A (en) 2020-09-08

Family

ID=72323747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010732967.4A Pending CN111632021A (en) 2020-07-27 2020-07-27 Probiotics toothpaste for preventing gingival atrophy

Country Status (1)

Country Link
CN (1) CN111632021A (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103263873A (en) * 2013-04-25 2013-08-28 威莱(广州)日用品有限公司 Solubiliser composition and preparation method thereof
CN105125445A (en) * 2015-09-16 2015-12-09 广州立白企业集团有限公司 Toothpaste composition
CN105534875A (en) * 2015-12-24 2016-05-04 重庆登康口腔护理用品股份有限公司 Anti-bacterial anti-allergy composition for oral care products, toothpaste and preparation method of toothpaste
CN106562923A (en) * 2016-08-12 2017-04-19 广州悦创实业有限公司 Oral care composition containing probiotics, and application of oral care composition to toothpaste
CN107080731A (en) * 2017-04-17 2017-08-22 江苏恩为众心生物医药有限公司 Probiotics periodontal nurses gel production technology
CN110507557A (en) * 2019-09-20 2019-11-29 介一生物工程技术（大连）有限公司 Fat-soluble toothpaste

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103263873A (en) * 2013-04-25 2013-08-28 威莱(广州)日用品有限公司 Solubiliser composition and preparation method thereof
CN105125445A (en) * 2015-09-16 2015-12-09 广州立白企业集团有限公司 Toothpaste composition
CN105534875A (en) * 2015-12-24 2016-05-04 重庆登康口腔护理用品股份有限公司 Anti-bacterial anti-allergy composition for oral care products, toothpaste and preparation method of toothpaste
CN106562923A (en) * 2016-08-12 2017-04-19 广州悦创实业有限公司 Oral care composition containing probiotics, and application of oral care composition to toothpaste
CN107080731A (en) * 2017-04-17 2017-08-22 江苏恩为众心生物医药有限公司 Probiotics periodontal nurses gel production technology
CN110507557A (en) * 2019-09-20 2019-11-29 介一生物工程技术（大连）有限公司 Fat-soluble toothpaste

Similar Documents

Publication Publication Date Title
AU2006320846B2 (en) Vehicles for oral care with Magnolia Bark Extract
US6503483B2 (en) Dental formulation
CN110996891B (en) Gel comprising chlorhexidine
EP2099416B1 (en) Anti-calculus dental composition and methods for using same
US6207137B1 (en) Dental formulation
US20070098650A1 (en) Dental formulation
US20090269288A1 (en) Black pearl toothpaste
JP2001500874A (en) Mouthwash consisting of calcium and phosphate ions in supersaturated solution
KR20100016416A (en) Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
CN107998036A (en) A kind of toothpaste and its manufacture method for oral cavity synthtic price index
WO1998056336A1 (en) Dental formulation
US6231836B1 (en) Folic acid dentifrice
JP2004532831A (en) Dental preparation
EP0486561B2 (en) Buccal composition containing s(+) ketoprofen
KR980008209A (en) Toothpaste composition
US20190167544A1 (en) Dual Compnent Oral Composition for Enhancing Remineralization of Teeth
JPS61286314A (en) Composition for oral cavity
CN111632021A (en) Probiotics toothpaste for preventing gingival atrophy
KR980008210A (en) Composition for promoting oral hygiene
US8961939B2 (en) Compositions and related methods for oral wellness
Nandhini et al. Comparison of the effectiveness of a commercially available herbal mouth rinse with chlorhexidine gluconate at the clinical and patient level
RU2545764C1 (en) Method of treating periodontitis
Kaur et al. The immediate Term effect of chewing commercially available Meswak (Salvadora persica) on levels of Calcium, Chloride, Phosphate and Thiocyanate in whole saliva
RU2777156C1 (en) Therapeutic and prophylactic composition for oral care for patients with bronchial asthma
JP7439352B2 (en) Composition for remineralizing tooth enamel

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination